Navigation Links
Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
Date:2/12/2013

KANSAS CITY, Kan. and BOSTON, Mass., Feb. 12, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has appointed Don Stitzenberg as Vice President of Manufacturing and Tammy Newbold as Vice President of Chemistry, Manufacturing and Controls. Don and Tammy are both seasoned veterans in the animal health industry and are valuable additions to Aratana's growing team of experts.

Ernst Heinen , DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We believe success is contingent on assembling the strongest possible team with proven expertise in all aspects of clinical and commercial drug development. For this reason, we are very pleased to welcome Don and Tammy to Aratana, each of whom are proven experts in establishing and executing quality development and manufacturing programs for animal health drugs."

Donald Stitzenberg
Prior to joining Aratana, Mr. Stitzenberg founded Carnegie Business Associates, an international supply chain consulting company, specializing in the pharmaceutical, chemical and cosmetics industries. He spent 33 years in executive positions at Merck and Co., Inc. in marketing, research, planning and manufacturing. He was Executive Director of Planning for Merck where he led the formation of Merck AgVet, Merck's Animal Health Division. Additionally, he negotiated the formation of Merial Inc., a global animal health joint venture with Rhone Merieux (now Sanofi).

Mr. Stitzenberg holds a BS in mathematics from Carnegie Mellon University where he is a Life Member of the Carnegie Mellon Board of Trustees. He also holds an MBA and an LLB and is a Member of the New Jersey Bar Association.

Tammy Newbold
Prior to joining Aratana, Ms. Newbold founded Ceris Consulting, which provides Chemistry, Manufacturing and Controls guidance to animal health companies seeking FDA approval of products. Ms. Newbold led the Worldwide Regulatory Chemistry, Manufacturing and Controls group at Merial, Inc. Her team identified worldwide regulatory requirements to define CMC for product development and also prepared worldwide pharmaceutical regulatory dossiers. She was an Associate Manager of Regulatory Affairs at Merck & Co., Inc. where she helped define worldwide CMC regulations for animal health products. Ms. Newbold served as a Process Development Scientist at Bausch & Lomb where she was in charge of manufacturing processes and facilities.  

Ms. Newbold earned her B.S. Degree in Biochemistry from the State University of New York at Stonybrook in 1986.

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals). Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market. For more information, please visit www.aratanatherapeutics.com.

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D./ Andrew Mielach
jdrumm@tiberend.com; (212) 375-2664
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Attagene , a Research ... U.S. Small Business Administration. The Tibbetts Award honors the Small Business Innovation ... and are considered the best of the best from the thousands of firms ...
(Date:1/13/2017)... -- Research and Markets has announced the addition of ... to 2021" report to their offering. ... The biosimilars market is expected to ... 2016, at a CAGR of 26.3%. The global ... and application. Factors such as rising incidence of various diseases, increasing ...
(Date:1/13/2017)... Island, NY (PRWEB) , ... January 13, 2017 ... ... teamed up with several companies to offer its customers three new solutions for ... probe would come in handy if a customer has an oddly-shaped sample that ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
Breaking Biology News(10 mins):